Review of Linezolid (KEY IJP************497)

• Ruchita D. Pawar,Rushikesh K.pokale ,Pratiksha K. Birangal,Surendra S. Bihani ,Sanjay S. Tavale,Prof. Dr. S.z.chemte

Abstract

Linezolid may have been the first antibiotic in the class of oxazolidinone antibiotics. This substance is a synthetic antibiotic that binds to rRNA to prevent bacteria from synthesising proteins. Additionally, it suppresses the initiation complex's formation during protein synthesis, which can shorten formed peptide chains and slow down the rate at which translation elongation occurs. Linezolid has been shown to bind a deep cleft of the 50S ribosomal subunit that is surrounded by 23S rRNA nucleotides through analysis of high-resolution structures of the drug. It has been demonstrated that 23S rRNA mutations cause linezolid resistance. More recent antibiotics that target resistant Gram-positive bacteria include linezolid, a synthetic oxazolidinone. Since 2000, linezolid has been widely accessible for the treatment of Gram-positive infections and is effective against a variety of Gram-positive bacteria.